Thermo Fisher Scientific reported QQ3 2025 revenue of $11.12 billion, up 4.9% year over year and 2.5% quarter over quarter, reflecting resilient demand across the Life Sciences Solutions and Analytical Instruments segments. Gross profit reached $4.652 billion with a gross margin of 41.8%, up from prior periods due to favorable mix and ongoing cost discipline, and operating income of $1.943 billion yielded an operating margin of approximately 17.5%. Net income was $1.616 billion, translating to a net margin of about 14.5% and EPS of $4.28 (diluted $4.27). Despite top-line strength, net income declined modestly year over year (-0.9%) and was flat to slightly down quarter over quarter, underscoring higher operating or non-operating costs and currency effects that impacted profitability, while the company continues to invest in R&D and go-to-market activities. Free cash flow per share stood at $4.85 with operating cash flow per share of $5.92, supporting a conservative payout and strong balance-sheet flexibility. The balance sheet exhibits solid leverage metrics (debt ratio ~0.346; debt to capitalization ~0.412) and a substantial cash generation profile, though working capital dynamics show a cash conversion cycle around 110 days, consistent with a capital-intensive high-margin science tools company.